Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Trial Profile

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Cell Cure Neurosciences
  • Most Recent Events

    • 15 Nov 2017 Results published in the Biotime Media Release
    • 15 Nov 2017 Data from this trial was presented at the annual American Academy of Ophthalmology (AAO), as reported in a Biotime media release.
    • 28 Aug 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top